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Abstract
Coagulase-negative staphylococci (CoNS) are frequently isolated in clinical specimens and are important reservoirs of resistance
genes. In 2019, the Brazilian government set the BrCAST/EUCAST (Brazilian Committee on Antimicrobial Susceptibility
Testing) guidelines as the national standard, resulting in changes in the interpretation of CoNS susceptibility tests. From
outpatients, disk-diffusion susceptibility of 65 CoNS cultures were evaluated and compared using classification criteria from
both CLSI and BrCAST/EUCAST. The isolates were identified using matrix assisted laser desorption ionization–time of flight
(MALDI-TOF), and the presence of the mecA gene was determined. The most prevalent species were Staphylococcus
saprophyticus (32.3%), S. haemolyticus (18.5%), and S. epidermidis (9.2%). Almost perfect agreement was seen between the
guidelines, except concerning oxacillin and gentamicin, and the prevalence of multidrug resistant isolates increased with the use
of BrCAST/EUCAST. Of all, 15 (23.1%) isolates, mainly S. epidermidis and S. haemolyticus, were positive for the mecA gene,
and only three were detected when using CLSI or BrCAST/EUCAST disk-diffusion screening. This, using either guideline,
could reveal the difficulty of determining oxacillin resistance. Using warning zones ormolecular methods might well be indicated
for CoNS. In conclusion, adoption of the BrCAST/EUCAST guidelines will result in certain artificial changes in epidemiological
susceptibility profiles, and clinicians and institutions should be aware of the possible implications.
Keywords Antimicrobial susceptibility testing . Brazilian Committee on Antimicrobial Susceptibility Testing . European
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Introduction
Coagulase-negative staphylococci (CoNS), mainly in skin
and mucous membranes, are a normal part of the human
microbiota. However, for many years, the bacteria had been
underrated as infectious agents, nowadays the pathogenic
potential of CoNS is well established, and they have been
associated with important opportunistic infections and mul-
tiple antibiotic resistance [1]. CoNS are a heterogeneous
group consisting of at least 39 species divided phylogenet-
ically into 14 cluster groups, where identification by classi-
cal phenotypic tests is difficult [2]. Although certain species
remain susceptible to various antibiotics, some strains are
frequently associated with resistance to multiple anti-
staphylococcal agents. The increase of oxacillin resistant
CoNS—as mediated by penicill in-binding protein
(PBP2a) modifications, encoded by the mecA gene—has
become a pressing concern [1, 3].
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The Clinical and Laboratory Standards Institute (CLSI)
M100 document (1986), originally from the former National
Committee for Clinical Laboratory Standards (NCCLS), is
worldwide one of the most used guidelines for interpretation
of antimicrobial susceptibility testing (AST) [4]. In 2005, the
Brazilian National Health Surveillance Agency (ANVISA)
obtained permission from CLSI to distribute a translated ver-
sion of M100-S15 to clinical laboratories [5], and henceforth
CLSI - M100-S15 became the principal guide used in Brazil.
Some laboratories, due to language barriers or lack of re-
sources to purchase annually updated versions, still use older,
outdated versions of M100-S15. In resource-poor settings
(like Brazilian laboratories), there is a need for suitable and
free AST guidelines. In 2019, after intense discussions by a
group of experts contracted by the Brazilian Ministry of
Health, the Brazilian Committee on Antimicrobial
Susceptibility Testing (BrCAST) guidelines were set as the
new standard for AST in Brazil [6].
In 2013, various Brazilian scientific societies united to
form BrCAST, aiming at consensus AST breakpoints for
Brazil. This is because, at the time, there were no CLSI
breakpoints for colistin or tigecycline and there were also
reported emergences of KPC-2 producing K. pneumoniae.
The BrCAST guidelines are based on the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) breakpoints, translated to Portuguese, and freely
available on their website [7]. EUCAST bases its clinical
breakpoints on epidemiological cut-off values and
pharmacokinetic-pharmacodynamic properties. Unlike CLSI,
the General Committee of EUCAST has representatives in
several countries including Brazil, and the pharmaceutical in-
dustry retains only a consultative role [8].
The aim of this study was to determine the CoNS species
frequency in samples of an outpatient population using both
the CLSI and the BrCAST/EUCAST AST guidelines and to
then compare the susceptibility/resistance rates of selected
antibiotics.
Materials and methods
The study included strains previously identified as CoNS from
outpatients of a clinical laboratory in Porto Alegre, Southern
Brazil, during the period of from March to August 2018. For
fast bacterial identification, isolates were plated on Mueller-
Hinton agar, and matrix-assisted laser desorption ionization–
time of flight (MALDI-TOF) methodology was performed out
in the Microflex LT (Bruker Corporation, USA) platform ac-
cording to the manufacturer’s specifications for direct colony
identification. The spectra were analyzed using MALDI
Biotyper 4.0 software and standard pattern matching with a
default setting in accordance with previously studies [9].
For susceptibility testing, the disk diffusionmethod accord-
ing to Kirby-Bauer was used [10]. Antimicrobial susceptibil-
ity for oxacillin using a cefoxitin 30 μg disk (CFO), ciproflox-
acin 5 μg (CIP), norfloxacin 10 μg (NOR), gentamicin 10 μg
(GEN), erythromycin 15 μg (ERY), clindamycin 2 μg (CLI),
trimethoprim-sulfamethoxazole 1.25/23.75 μg (TMP/SMX),
and chloramphenicol 30 μg (CLO) (SENSIDISC, DME,
Brazil) was performed on Mueller-Hinton agar (TM Media,
Titan Biotech, India) and using a suspension equivalent to
MacFarland 0.5 from overnight cultures followed by incuba-
tion at 35 ± 1 °C for 20 and 24 h. Inhibition zone diameters
were determined and interpreted according to the CLSI 2019,
BrCAST/EUCAST 2019, and CLSI 2018 guidelines for
norfloxacin (see supplementary file 1) [4, 11, 12].
Multiplexed PCR for detection of the mecA gene and de-
termination of SCCmec type was performed for the isolates as
previously described [13].
For statistical analysis, the percentage concordance rate
between the two guidelines was compared. Cohen’s Kappa
coefficient was used to measure the guideline agreement rate
for each antimicrobial; p ≤ 0.05 was considered statistically
significant, and all analyses were done using IBM SPSS ver-
sion 20.0 for macOS (IBM Corporation, USA). Also, the re-
search protocol was approved by an ethics committee.
Results
A total of 65 CoNS strains were included in this study, 90.7%
of the isolates were obtained from urine, 6.2% from blood,
and 3.1% from secretions. The average patient age was 41 ±
23.2 years (ranging from 9 to 89), and the majority of patients
52/63 (80%) were female.
Within the overall sample population, the MALDI-TOF
methodology for rapid identification revealed the presence
of at least seven CoNS species. Of all, 47 (72.3%) of the
isolates were consistently identified at the species level. The
remainder 18 (27.7%) did not fulfill the conditions for identi-
fication at the species level, being thus identified as
Staphylococcus spp., of these, eight were best matched with
S. saprophyticus, four with S. haemolyticus, three with
S. lugdunensis, two with S. epidermidis, and one with
S. cohnii. Table 1 summarizes the CoNS species identified
according to sample origin.
In the antimicrobial susceptibility testing (AST), the
specie-antibiotic susceptibilities were equal in both guide-
lines, agreement for each antibiotic ranged from 89.1 to
100%, with noted susceptibilities in both guidelines of
96.9% for CLO, 86.2% for CIP, 81.5% for CLI, 49.2% for
ERY, 86.8% for NOR, and 63.1% for TMP/SMX. On the
other hand, for GEN we observed a susceptibility of 93.8%
with CLSI and 84.4% with BrCAST/EUCAST. For oxacillin,
we observed a susceptibility of 93.8% with CLSI and of
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96.9% using the BrCAST/EUCAST criteria. Kappa analysis
presented perfect agreement for CLO and CLI (κ = 1), and
almost perfect agreement for CIP (κ = 0.936), ERY (κ =
0.972), NOR (κ = 0.887), and TMP/SMX (κ = 0.968).
Substantial agreement was observed with oxacillin using a
CFO disk (κ = 0.652), and only moderate agreement was ob-
served for GEN (κ = 0.458). Comparing the test results using
both guidelines, we noted five minor divergences; in which
CLSI classified isolates as intermediate and BrCAST/
EUCAST classified isolates as resistant. Six major diver-
gences were observed for GEN, being classified as susceptible
by CLSI and yet resistant by BrCAST/EUCAST. For the ox-
acillin criteria, the results of two isolates; S. haemolyticus and
S. saprophyticus were considered to be major errors, leading
to classification by CLSI as resistant, and by BrCAST/
EUCAST as susceptible. Table 2 summarizes the susceptibil-
ities, agreement, and kappa statistics for both guidelines. Of
the 65 CoNS tested, 10 (15.4%) - CLSI and 14 (21.9%) -
BrCAST/EUCAST were resistant to at least three antimicro-
bial classes and were therefore classified as multidrug resistant
(MDR) [9] with a concordance of 93.8% (Table 3).
Positives for the mecA gene were observed in 15 isolates
(23%) (Table 4), three were classified as resistant by at least
one guideline, and 12 (18.5%) were classified as susceptible,
an error for both guidelines. Figure 1 presents the distributions
of the CFO disk inhibition zone diameters observed in the
study by criteria for mecA screening of staphylococci using
CLSI and BrCAST/EUCAST. Inducible resistance to CLI was
observed as positive for seven isolates, (two S. saprophyticus,
two S. warneri, one S. epidermidis, one S. haemolyticus, and
one Staphylococcus sp.), when using D test - (disk approxi-
mation test) detection.
Discussion
Due to the high association of CoNS with healthcare-acquired
(nosocomial) infections [14, 15], there are few reports
concerning epidemiology in outpatients. Our study did not in-
clude patients from healthcare facilities, and the samples were
composed mainly of urine specimens. Indeed, some CoNS are
frequent uropathogens, such as S. saprophyticus in young and
middle-aged women [16]. Before MALDI-TOF became avail-
able, identification of CoNS at the species level was not routine-
ly performed [14]. In urine specimens of a like population of
patients in Ghana, a high prevalence of S. haemolyticus (75%),
followed by S. epidermidis (13%) and S. hominis, and as in our
study S. warneri, S. lugdunensis, and S. condimenti [17], was
also observed, yet surprisingly S. saprophyticus was not report-
ed. This might be indicative of a greater diversity of CoNS
species in outpatients and of a possible rise of unfamiliar isolates
such as S. condimenti, which was first reported as a pathogen in
2014 [18]. The data suggest that the S. epidermidis–like group,
specially S. haemolyticus, seems to have an important role as
gram-positive uropathogens in both patients and outpatients [14,
17, 19].
Table 2 Susceptibilities of CoNS to antibiotics, with concordance and kappa statistics for the CLSI and BrCAST/EUCAST guidelines
Antimicrobial agent CLSI BrCAST/EUCAST Concordance % Kappa P
S (%) I (%) R (%) S (%) I (%) R (%)
Chloramphenicol 62 (96.9) 0 2 (3.1) 62 (96.9) 0 2 (3.1) 100.0% 1 < 0.000
Ciprofloxacin 56 (86.2) 1 (1.5) 8 (12.3) 56 (86.2) 0 9 (13.8) 98.5% 0.936 (± 0.060) < 0.000
Clindamycin 53 (81.5) 0 12 (18.5) 53 (81.5) 0 12 (18.5) 100.0% 1 < 0.000
Erythromycin 32 (49.2) 4 (6.2) 29 (44.6) 32 (49.2) 3 (4.6) 30 (46.2) 98.5% 0.972 (± 0.028) < 0.000
Gentamicin 60 (93.8) 1 (1.6) 3 (4.7) 54 (84.4) 0 10 (15.6) 89.1% 0.458 (± 0.151) < 0.000
Norfloxacin 33 (86.8) 1 (2.6) 4 (10.5) 33 (86.8) 0 5 (13.2) 97.4% 0.887 (± 0.100) < 0.000
Oxacillin* 61 (93.8) 0 4 (6.2) 63 (96.9) 0 2 (3.1) 96.9% 0.652 (± 0.227) < 0.000
Trimethoprim-sulfamethoxazole 41 (63.1) 2 (3.1) 22 (33.8) 41 (63.1) 1 (1.5) 23 (35.4) 98.5% 0.968 (± 0.031) < 0.000
I intermediate, R resistant, S sensible
*Cefoxitin disk
Table 1 Species of CoNS species identified according to sample origin
Identification Urine Blood Secretion Total (%)
S. saprophyticus 21 0 0 21 (32.3)
S. haemolyticus 12 0 0 12 (18.5)
S. epidermidis 2 4 0 6 (9.2)
S. warneri 3 0 1 4 (6.2)
S. lugdunensis 2 0 0 2 (3.1)
S. caprae 1 0 0 1 (1.5)
S. condimenti 1 0 0 1 (1.5)
Staphylococcus spp. 17 0 1 18 (27.7)
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Though CoNS present fewer virulence factors than
S. aureus, they still maintain an active role in antimicrobial
resistance, serving as reservoirs of many resistance genes and
contributing to the spreading of multiresistance between
staphylococci [20]. That being said, the determination of an
accurate CoNS susceptibility profile should carefully pursued.
CLSI, despite its cost and remaining untranslated to
Portuguese, has been the standard guideline in Brazilian lab-
oratories for interpreting AST. With AST, it is critical for
guidelines to be up to date, free, and readily available. Since
2019, the Brazilian Ministry of Health has adopted BrCAST/
EUCAST as the standard guideline for Brazilian laboratories
[6], yet CLSI and BrCAST/EUCAST methods lead to differ-
ing disk diffusion breakpoints and consequently divergent ep-
idemiological susceptibility profiles.
CLSI and EUCAST susceptibility profiles have been com-
pared in studies, and significant changes have been reported
concerning certain pathogens [21–26]. Due to its more restric-
tive breakpoints, lower susceptibility rates have been observed
for EUCAST [21]. However, the impact of this change on
CoNS susceptibility profiles has not been fully explored, and
in our comparison study, most CoNS-antibiotic combinations
presented perfect or almost perfect agreement (except for
GEN and Oxacillin).
Several countries have been progressively moving to im-
plement EUCAST as a standard AST guideline, and for
S. aureus, (excluding use of aminoglycosides) some studies
evaluating the impact of this change in staphylococci show
excellent correlations between both guidelines. The use of
EUCAST criteria for minimal inhibitory concentration
(MIC) results in a significant reduction in GEN susceptibility
in S. aureus [22–24]. One study with CoNS observed the same
for S. haemolyticus but not for S. lugdunensis. A plausible
explanation is the lower number of resistance mechanisms
observed in S. lugdunensis [25]. The contrast observed for
GEN is due to the more stringent BrCAST/EUCAST
breakpoint, which leads to a higher resistance rate for staphy-
lococci. The CLSI breakpoint for GEN for staphylococci is ≥
Table 3 Susceptibilities profiles of MDR CoNS according to CLSI and BrCAST/EUCAST guidelines
Species CLSI BrCAST/EUCAST
Number of isolates Antimicrobial resistance profiles Number of isolates Antimicrobial resistance profiles
S. epidermidis 3 OXA - CIP - TMP/SMX 4 OXA - CIP - GEN - TMP/SMX
CLI - ERY - CIP CLI - ERY - CIP
CLI - ERI - CIP - TMP/SMX CLI - ERI - CIP - TMP/SMX
GEN - TMP/SMX - NOR
S. haemolyticus 2 CLI - ERY - GEN - NOR 5 CLI - ERY - GEN - NOR
ERY - GEN - TMP/SMX ERY - GEN - TMP/SMX
ERY - CIP - GEN - TMP/SMX
OXA - ERY - GEN
CIP - GEN - TMP/SMX - NOR
S. warneri 2 CLI - ERY - TMP/SMX 2 CLI - ERY - TMP/SMX
CLI - ERY - TMP/SMX CLI - ERY - TMP/SMX
S. saprophyticus 1 OXA - CLI - ERY - TMP/SMX 1 CLI - ERY - TMP/SMX
Staphylococcus spp. 2 ERY - CIP - TMP/SMX -NOR 2 ERY - CIP - GEN- TMP/SMX -NOR
CLI - ERY - TMP/SMX CLI - ERY - TMP/SMX
CLI clindamycin, CIP ciprofloxacin, ERYerythromycin,GEN gentamicin, NOR norfloxacin,OXA oxacillin, TMP/SMX trimethoprim-sulfamethoxazole
Table 4 Distribution of SCCmec
types according to CoNS species Species Number of mecA-positive isolates SCCmec type
III IV V
S. epidermidis 5 0 3 2
S. haemolyticus 5 1 3 1
S. saprophyticus 1 0 1 0
Staphylococcus spp. 4 1 1 2
Total 15 2 (13.3%) 8 (53.3%) 5 (33.3%)
1074 Braz J Microbiol (2020) 51:1071–1078
15 mm [4], conversely, the BrCAST/EUCAST breakpoint for
CoNS is ≥ 22 mm. Currently, BrCAST/EUCAST has a less
rigorous GEN breakpoint for S. aureus [12], and a review of
CoNS breakpoints might be in order to prevent false,
BrCAST/EUCAST-related epidemiological profile changes
in Brazil.
Organizing disagreements into minor and major divergences,
we found fiveminor divergences between the guidelines. In each
case, CLSI classified the isolate as intermediate, whereas
BrCAST/EUCAST classified the isolate as resistant. In three
cases, this resulted in an MDR classification. Disagreement for
ERY as an S. haemolyticus isolate resistant to oxacillin was ob-
served, and a different S. haemolyticus presented disagreement
for CIP. Discordanceswere also noted forGEN andNORagainst
another S. epidermidis. Reclassification to MDR can change re-
gional epidemiological profiles and influence antimicrobial se-
lection by clinicians.
Even though there is perfect agreement observed between
the guidelines in the literature for oxacillin MICs in staphylo-
cocci [24–26], the disk diffusion method remains the standard
tool for detecting oxacillin resistance and the changes between
the guidelines are relevant. Oxacillin resistance is used as a
predictor for the presence of the mecA gene and consequently
of resistance to beta-lactams, (penicillins, most cephalospo-
rins, and carbapenems), this may well affect patient manage-
ment. CLSI requires differing conditions according to species,
with incubation of 16–18 h and using a cefoxitin 30-μg disk
with a cut-off of ≤ 21 mm for S. lugdunensis; for
S. epidermidis and other CoNS, it requires an incubation of
24 h and cut-off of ≤ 24 mm (except S. pseudintermedius and
S. schleiferi). An oxacillin 1-μg disk with cut-offs of ≤ 17 mm
is mandatory for S. pseudintermedius and S. schleiferi yet can
also be used for S. epidermidis [4]. On the other hand, for all
CoNS species except S. epidermidis and S. pseudintermedius
(e.g. S. capitis, S. cohnii, S. haemolyticus, S. hominis, S.
hyicus, S. lugdunensis, S. saprophyticus, S. schleiferi, S.
sciuri, S. simulans, S. warneri and S. xylosus), BrCAST/
EUCAST requires incubations of 18 ± 2 h, and a cefoxitin
30-μg disk with a cut-off of < 22 mm. For S. epidermidis
and non-species level identified CoNS, BrCAST/EUCAST
requires a cut-off of < 25mm. For S. pseudintermedius screen-
ing, BrCAST/EUCAST requires use of a 1-μg oxacillin disk
and a cut-off of < 20 mm [12].
In our results, four CoNS were classified as oxacillin resis-
tant by CLSI and two by BrCAST/EUCAST, revealing only
partial agreement. Despite the specific conditions for
S. epidermidis in BrCAST/EUCAST, other species included
in the S. epidermidis–like group, such as S. haemolyticus, are
not covered in this criteria, and onemecA-positive isolate with
a borderline inhibition zone detected by CLSI was classified
as oxacillin susceptible by BrCAST/EUCAST. In fact,
S. haemolyticus is frequently MDR [20, 25] developing resis-
tance to beta-lactams. In our sample, 41.7% harbored mecA,
three of these (with inhibition zones of 26 mm, 26 mm, and
29 mm) were not detected using the disk diffusion screening
criteria of either guideline. In a previous study with Brazilian
isolates, approximately 60% of the community isolates and
100% of the blood isolates were positive for mecA [27].
Fig. 1 Distribution of inhibition zone diameters for CoNS and screening criteria for mecA gene by CLSI and BrCAST/EUCAST
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CLSI and BrCAST/EUCAST have different breakpoints
for oxacillin MIC and disk diffusion in S. saprophyticus (re-
spectively 0.5 mg/L and ≤ 24 mm; and 2.0 mg/L and <
22 mm,) [4, 12]. One mecA-negative isolate was classified
as resistant by CLSI, and one mecA-positive isolate was clas-
sified as susceptible by both guidelines. For S. saprophyticus,
oxacillin resistance needs to be careful evaluated since previ-
ous studies have observed differing results from the guideline
criteria for MIC, disk diffusion, and mecA presence [27, 28].
The presence of the mecA gene in S. epidermidis was high
(83%), but only one of five isolates was detected using the
screening criteria for disk diffusion. The isolates classified as
oxacillin susceptible presented large CFO disk inhibition
zones (27 to 40 mm), and only one isolate met the suggested
BrCAST/EUCAST confirmation criteria [12].
In resource-poor laboratory settings, CoNS are frequently
not identified at the species level due to the limitations of
classical phenotypic tests [14]. In our sample, even with the
use of MALDI-TOF, 27.7% of isolates were not confidently
identified at the species level, thus the importance of evaluat-
ing the CLSI and BrCAST/EUCAST guidelines for determi-
nation of oxacillin resistance for Staphylococcus spp.
According to CLSI, using the CFO disk is an acceptable meth-
od for Staphylococcus spp. or oxacillin MIC. However, the
MIC may emphasize resistance, and results between 0.5 and
2 mg/L must be tested for mecA [4]. BrCAST/EUCAST indi-
cates using the CFO disk with no recommendations of MIC
breakpoints for CoNS not identified at species level [12]. Of
18 CoNS not identified at the species level, four (22%)—best
matched to S. haemolyticus—harbored the mecA gene, and
both guidelines failed in screening for this resistance
mechanism.
It is also important to note that the oxacillin 1-μg disk is
recommended by CLSI for S. pseudintermedius and
S. schleiferi and by BrCAST/EUCAST for S. pseudintermedius
(cut-off ≤ 17mm and < 20mm, respectively) to screen formecA.
CLSI also recommended oxacillin MIC as an acceptable meth-
odology for all CoNS [4, 12]. Despite this consideration, in our
sample we did not identify these two species.
The vast majority of clinical CoNS possess the mobile
genetic element SCCmec that harbors the mec gene [2].
Detection of oxacillin resistance in these isolates is a huge
challenge since agreement between phenotypic and molecular
methods oscillates among strains. Pinheiro et al. [27] attributes
this to resistance heterogeneity, with borderline resistance be-
ing a very common phenomenon. In 2019, BrCAST/
EUCAST introduced a warning zone (25–27 mm) for
S. epidermidis called the Area of Technical Uncertainty
(ATU) indicating the need of confirming susceptibility cate-
gorization, by using an alternative test [12]. The adoption of
the ATU warning for all CoNS might increase oxacillin resis-
tance detections in our study, especially in S. haemolyticus
isolates.
MDR strains frequently acquire resistance to macrolides
and related antibiotics. Indeed, some SCCmec harbor genes
for resistance to ERYand others antibiotics [2].Macrolides are
not used for first-line treatment of urinary infections, and the
high rates of acquired ERY resistance observed could indicate
a change in the human microbiota due to the overuse of these
agents in the community. The mutation in 23S rRNA mediat-
ed by the erm gene is the most frequently noted mechanism of
resistance to ERY, and the presence of these genetic elements
generally results in a phenotype of resistance to macrolides,
lincosamides, and streptogramin B (MLS), which can be ei-
ther constitutive (cMLS) or inducible (iMLS). As other mech-
anisms, efflux pumps encoded by the msrA gene mediate re-
sistance to MLS, and drug modification is encoded by the lnu
gene [29]. The iMLS phenotype occurs in strains that carry
erm genes but are susceptible to CLI in AST. Clindamycin
treatment in patients with iMLS resistance may lead to thera-
peutic failure [30], and the disk approximation test, or D test,
is used to detect this phenotype. Of the isolates resistant to
macrolides, 7/30 (23.3%) were positive to phenotype iMLS.
For the cMLS phenotype, 3/30 (10%) were positive, with 20/
30 (66.6%) of the isolates being resistant only to macrolides.
All isolates resistant to CLI were also resistant to ERY. The
prevalence of macrolide-resistant phenotypes in CoNS might
vary according to regions and populations that use macrolides;
in fact, our prevalence for iMLS was greater than previous
studies around the world, 11.8 to 15.2% [29–31].
There are few studies evaluating the use of CLSI and
EUCAST guidelines for CoNS, and our study presents some
limitations. First, the limited sample size in a single laboratory
may interfere in the epidemiology. The AST comparison re-
sults are limited to antibiotics where both guidelines indicated
the same disk concentrations. And also, we did not evaluate
nitrofurantoin (important in treating urinary infections), peni-
cillin, ampicillin, or linezolid. Our purpose was to evaluate the
implications of switching AST guidelines and not to design an
experiment establishing which presents better performance in
determining susceptibility to oxacillin. However, evaluation
of oxacillin disk performance, or the oxacillin MICs for all
CoNS, could be important data for analysis of this issue.
Finally, we did not use molecular typing tools such as
MLST or PFGE to evaluate clonality.
CoNS are often underestimated as etiological agents of
human infections, especially in outpatients. The introduction
of MALDI-TOF led to recognition of the great species diver-
sity; and that S. haemolyticus seems to have an important role
as urinary pathogen with the ability to accumulate antibiotic
resistant determinants. Our research revealed acceptable con-
cordance between CLSI and BrCAST/EUCAST except when
using aminoglycosides. We note that determination of oxacil-
lin susceptibility in CoNS has many pitfalls for both guide-
lines. When investigating oxacillin resistance, the use of a
warning zone (ATU) for all CoNS, more than one
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susceptibility test, or a specialized molecular methodology
may well be indicated. In conclusion, when adopting the
BrCAST/EUCAST guidelines and comparing data during
and after implementation, clinicians and institutions should
be aware of the implications of the change.
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